Overview

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

Status:
Completed
Trial end date:
2018-12-07
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Amlodipine
Rosuvastatin Calcium